Orchard Venture Partners

Verlume specializes in subsea power hub technology that focuses on generating, storing, and supplying electrical power from ocean currents and tides. The company's innovative solutions are designed to help clients in underwater, offshore, and onshore sectors reduce their carbon footprint and decarbonize their operations. By converting renewable energy from marine environments into usable electrical power, Verlume enables its clients to harness clean energy while minimizing environmental impact.

GuideCX, Inc. is a company that specializes in client onboarding and project implementation software, designed to facilitate a smooth transition between sales and implementation processes. Founded in 2017 and based in Draper, Utah, GuideCX serves a variety of industries, including software as a service (SaaS), automotive, education, finance, and health. The platform enables users to automate tasks, view project statuses, and communicate updates effectively, providing a transparent experience for clients. With over 300,000 successful onboarding projects completed, GuideCX emphasizes engagement and efficiency, offering customizable templates and purpose-built integrations that enhance user experience. The platform is designed for easy integration with existing customer relationship management systems and includes robust reporting features to help manage customer expectations and improve overall project outcomes.

Verlume specializes in subsea power hub technology that focuses on generating, storing, and supplying electrical power from ocean currents and tides. The company's innovative solutions are designed to help clients in underwater, offshore, and onshore sectors reduce their carbon footprint and decarbonize their operations. By converting renewable energy from marine environments into usable electrical power, Verlume enables its clients to harness clean energy while minimizing environmental impact.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

Base4 Biotechnology is focused on advancing RNA-targeted therapeutics through innovative small molecule modulation aimed at addressing previously untreatable diseases. Utilizing a proprietary structure-based discovery platform, the company integrates advanced computational technologies with experimental validation to explore and unlock the potential of RNA targets. This approach allows Base4 to tackle complex diseases across various therapeutic areas, including neurology, oncology, and rare diseases. By bridging the gap between computational discovery and practical application, Base4 aims to contribute significantly to the development of transformative medicines in the healthcare industry.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

Kereos, Inc. is a biopharmaceutical company based in Saint Louis, Missouri, specializing in the development of targeted molecular imaging agents and therapeutics aimed at detecting and treating cancer and cardiovascular diseases. Established in 1999, Kereos utilizes a nanoscale drug delivery technology that enhances the targeting and efficacy of various therapeutic compounds, including existing drugs, new candidates, and those that may be too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001, a cancer therapeutic that combines paclitaxel with a targeted nanodroplet, KER-1002, which integrates a natural anti-tumor agent, and KER-1003, known for its anti-angiogenic properties. Additionally, Kereos offers diagnostic solutions such as KER 0001, designed to detect angiogenesis. The company also collaborates with pharmaceutical and imaging firms to further develop its MRI agents and targeted chemotherapeutics for solid tumors and cardiovascular applications.

Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies for patients with hematology and oncology needs. The company's lead drug candidate, momelotinib, is an orally bioavailable inhibitor targeting JAK1, JAK2, and ACVR1, which has undergone two completed Phase 3 trials for myelofibrosis treatment. Additionally, Sierra Oncology is advancing SRA737, a small molecule inhibitor of Checkpoint kinase 1 currently in Phase 1/2 clinical trials, and SRA141, an inhibitor of cell division cycle 7 kinase, which is in preclinical development. Founded in 2003 and headquartered in Vancouver, Canada, Sierra Oncology aims to provide targeted therapies for rare forms of cancer, leveraging scientific expertise to address limitations in existing treatments and improve patient outcomes. The company was previously known as ProNAi Therapeutics, Inc. before its name change in January 2017.